INVESTOR IN THE FAMILY Radio
INVESTOR IN THE FAMILY Radio

106 Dividend Sensei - Why You (And Another Company) Should Buy Gilead

October 18, 201632 min
Adam, the "Dividend Sensei" and I sit down to discuss Gilead (GILD). Adam provides a fire hydrant blast of information and expectations regarding Gilead, including some thoughts on the possibility of Gilead being acquired. If you'd like to jump ahead in the interview to the discussion on Gilead's acquisition prospects, it begins around the 20 minute mark of the interview. A quick overview: Gilead's free cash flow prospects. Company's track record, culture, R&D, manufacturing process, patent portfolio, and pipeline. Adam's price targets for Gilead. Who might purchase Gilead and for how much. How he plans to respond if price falls any further. Much more... Companies Mentioned: Pfizer (PFE), JNJ (JNJ), Merck (MRK), Amgen (AMGN), AstraZeneca (AZN), AbbVie (ABBV)

Chat About 106 Dividend Sensei - Why You (And Another Company) Should Buy Gilead